Table 4 Demographic and clinical characteristics for the different genotypes of rs4353135 in CD patients

Gender

 Male (n = 488)

 Female (n = 493)

234 (50.2%)

232 (49.8%)

207 (50.5%)

203 (49.5%)

47 (44.8%)

58 (55.2%)

0.557

Age at diagnosis [years]

 Median, q25–q75,

 Min–max

24.4, 18.2–34.7,

1.1–81.0

23.9, 17.9–32.5,

0.8–81.4

25.2, 17.4–35.1,

1.6–73.7

0.465

Disease duration [years]

 Median, q25–q75,

 Min–max

12.4, 7.4–21.0,

0.1–52.0

12.2, 7.2–21.2,

0.2–56.6

9.9, 5.7–19.4,

1.2–44.0

0.239

Complications*

 No (n = 345)

 Yes (n = 636)

159 (34.1%)

307 (65.9%)

147 (35.9%)

263 (64.1%)

39 (37.1%)

66 (62.9%)

0.765

Fistula, abscess or anal fissure*

 No (n = 518)

 Yes (n = 463)

247 (53.0%)

219 (47.0%)

221 (53.9%)

189 (46.1%)

50 (47.6%)

55 (52.4%)

0.513

Focus on the “yes”:

 Perianal fistula

 Other fistula

 Fissure

 Abscess

117 (53.4%)

84 (36.4%)

66 (30.1%)

120 (54.8%)

93 (49.2%)

84 (44.4%)

52 (27.5%)

107 (56.6%)

33 (60.0%)

15 (27.3%)

22 (40.0%)

26 (47.3%)

0.356

0.066

0.207

0.474

 Surgery for fistula

114 (52.1%)

102 (54.0%)

30 (54.5%)

0.913

Stenosis*

 No (n = 551)

 Yes (n = 430)

256 (54.9%)

210 (45.1%)

239 (58.3%)

171 (41.7%)

56 (53.3%)

49 (46.7%)

0.501

Focus on the “yes”:

 Operation

 Dilation

 No intervention

110 (52.4%)

81 (38.6%)

110 (52.4%)

83 (48.5%)

72 (42.1%)

98 (57.3%)

28 (57.1%)

16 (32.7%)

28 (57.1%)

0.541

0.469

0.595

CDAI—maximal value throughout follow-up

 Median, q25–q75,

 Min–max

60, 26–109,

0–345

70, 31–126,

4–405

70, 34–118,

6–479

0.071

Reported flare*

 No (n = 477)

 Yes (n = 504)

240 (51.5%)

226 (48.5%)

185 (45.1%)

225 (54.9%)

52 (49.5%)

53 (50.5%)

0.164

Flare possibly or highly related to (focus on yes):

 NSAIDs

 Antibiotics

 GI tract infection

 Other infection

 Treatment decr. / disc

 Other medication

5 (2.2%)

5 (2.2%)

35 (15.5%)

15 (5.8%)

50 (22.1%)

1 (0.4%)

4 (1.8%)

3 (1.3%)

42 (18.7%)

21 (9.3%)

70 (31.1%)

5 (2.2%)

2 (3.8%)

1 (1.9%)

7 (13.2%)

3 (5.7%)

14 (26.4%)

1 (1.9%)

0.613

0.710

0.545

0.347

0.097

0.180

Flare management (focus on the yes):

 Hospitalization

 Ambulatory

 Surgery

 Drug therapy

35 (15.5%)

59 (26.1%)

18 (8.0%)

198 (87.6%)

42 (18.7%)

59 (26.2%)

26 (11.6%)

195 (86.7%)

9 (17.0%)

11 (20.8%)

6 (11.3%)

45 (84.9%)

0.652

0.753

0.398

0.828

Focus on the hospitalizations:

 Total days of hosp.

 Median, q25–q75,

 Min–max

7, 0–12,

0–47

5.5, 2–17,

0–86

12, 3–20,

0–50

0.646